Zacks.com on MSN2h
FDA Accepts SNY and REGN's Dupixent Re-Submitted sBLA for Urticaria
Sanofi SNY and partner Regeneron REGN announced that the FDA has accepted their resubmitted supplemental biologics license ...
The Pharma Letter7h
Opuviz is latest EC-approved ophthalmology biosimilar
Following US approval in May this year, South Korea’s Samsung Bioepis and US biotech Biogen have now won approval from the ...
Jasper Therapeutics: Briquilimab's Potential In Chronic Urticaria And Asthma
Jasper Therapeutics faces financial challenges but strong buy ratings. Read why JSPR stock is poised for growth amid risks ...
Pharmabiz17h
US FDA accepts for review the resubmission of sBLA for Dupixent to treat chronic spontaneous urticaria
US FDA accepts for review the resubmission of sBLA for Dupixent to treat chronic spontaneous urticaria: Paris Monday, November 18, 2024, 11:00 Hrs [IST] The US Food and Drug Admin ...
The Pharma Letter22h
FDA accepts Dupixent sBLA resubmission for CSU
The US Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental Biologics License ...